Research Education

PerformanceLabsUK supplies independently tested research reference materials for in vitro laboratory and scientific research use only, not for human or veterinary use.

Retatrutide: Triple Receptor Agonist Research Overview

Compound Research

This page summarises findings from published academic literature. It does not describe or endorse use in humans or animals, and does not imply any treatment, prevention or cure of any condition.

Retatrutide is a synthetic peptide studied in metabolic receptor pharmacology research as a triple receptor agonist. This page gives a general, research-framed overview of what published literature examines, for research reference purposes only.

What Is Retatrutide?

Retatrutide is a structurally engineered peptide studied for its activity at three separate receptors: the GLP-1 receptor, the GIP receptor, and the glucagon receptor. Its classification as a triple agonist is what distinguishes it, in research literature, from single-receptor or dual-receptor agonists studied in the same broader field.

Areas of Published Research

Published research on Retatrutide sits within the broader field of metabolic receptor pharmacology. Studies in this area typically examine receptor binding characteristics, cellular signalling pathways activated by multi-receptor engagement, and comparative pharmacology relative to other agonists studied in the same class. This research is conducted in laboratory and pre-clinical settings.

How Retatrutide Differs From Dual and Single Agonists

Research literature distinguishes compounds in this field by how many receptors they are studied to engage. A single-receptor agonist is studied for activity at one target, most commonly the GLP-1 receptor. A dual agonist is studied for activity at two receptors, such as GLP-1 and GIP together. A triple agonist, the class Retatrutide is studied within, is examined for activity across three receptor targets simultaneously. This structural classification is a matter of pharmacological research design, not a claim about outcomes.

Comparing Agonist Research Classes

Class	Receptor targets studied
Single agonist	One receptor, most commonly GLP-1
Dual agonist	Two receptors, such as GLP-1 and GIP
Triple agonist	Three receptors: GLP-1, GIP and glucagon

Frequently asked questions

Is Retatrutide approved for any medical use?

This page summarises research literature only and does not address regulatory approval status for any jurisdiction. Retatrutide supplied by PerformanceLabsUK is intended strictly for in vitro laboratory research use, not for medical application in humans or animals.

Is Retatrutide tested before dispatch?

Yes. Every batch is independently tested and issued with a batch-specific Certificate of Analysis before dispatch.

Is Retatrutide intended for human or animal use?

No. All compounds discussed on this site are supplied strictly for in vitro laboratory research use only, and are not intended for human or animal administration.

Where can I find the Certificate of Analysis for Retatrutide?

Batch-specific Certificates of Analysis are published in the PerformanceLabsUK COA library, referenced against the batch number shown on the product page.

Does this page constitute medical advice?

No. This page is provided for educational purposes only and does not constitute medical advice. Consult a qualified healthcare professional for any medical concern.

Research content only. PerformanceLabsUK Ltd, company number SC883220, registered in Scotland.